[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-462430-105":59,"doc-detail-462430-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","lessons-learnt-from-the-belimumab-trials-in-systemic-lupus-erythematosus","Lessons Learnt from the Belimumab Trials in Systemic Lupus Erythematosus","","Belimumab, a human monoclonal antibody targeting B-cell activating factor (BAFF), has advanced systemic lupus erythematosus (SLE) management beyond initial Phase III RCTs. More than 50 post hoc analyses consistently show higher chances of meaningful disease activity reductions, sustained low disease activity, and improved health-related quality of life, especially in serologically active SLE. Organ-specific evidence highlights musculoskeletal and mucocutaneous benefits, while BLISS-LN results show reduced renal flare rates, improved glomerular filtration, and better histology. Long-term extension and real-world data confirm durable efficacy, safety, and reduced glucocorticoid use and healthcare utilization.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/lessons-learnt-from-the-belimumab-trials-in-systemic-lupus-erythematosus/462430/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/lessons-learnt-from-the-belimumab-trials-in-systemic-lupus-erythematosus/462430.png","ImageObject",300,407,{"name":92,"@type":93},"Sarah ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is belimumab and what mechanism does it target in SLE?","Question",{"text":113,"@type":114},"Belimumab is a human monoclonal antibody that works against B-cell activating factor (BAFF). It targets pathways involving B-cell survival relevant to the pathogenesis of SLE.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What do post hoc analyses of belimumab RCT data show?",{"text":118,"@type":114},"Post hoc analyses indicate belimumab increases the likelihood of meaningful reductions in disease activity, sustained low disease activity, and improved health-related quality of life outcomes, with stronger effects in serologically active SLE.",{"name":120,"@type":111,"acceptedAnswer":121},"What benefits are reported for renal outcomes in the BLISS-LN trial?",{"text":122,"@type":114},"The review reports benefits of belimumab across multiple renal outcomes, including reduced renal flare rates, improved glomerular filtration rate, and improved histological findings in repeat kidney biopsies.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},462430,1791098452,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Review  \nLessons Learnt from the Belimumab Trials in Systemic Lupus Erythematosus  \nLeonardo Palazzo 1, Alexander Tsoi 1, Dionysis Nikolopoulos 1, * and Ioannis Parodis 1,2, *  \nAcademic Editor: Gian Marco Ghiggeri  \nReceived: 25 November 2025  \nRevised: 14 December 2025  \nAccepted: 15 December 2025  \nPublished: 19 December 2025  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Center for Molecular Medicine (CMM), SE-171 76 Stockholm, Sweden  \n2 Department of Rheumatology, Faculty of Medicine and Health, Örebro University, SE-701 82 Örebro, Sweden  \n* Correspondence: [dionysis.nikolopoulos@ki.se](dionysis.nikolopoulos@ki.se) (D.N.); [ioannis.parodis@ki.se](ioannis.parodis@ki.se) (I.P.)  \nAbstract  \nBelimumab, a human monoclonal antibody that works against B-cell activating factor (BAFF), has significantly advanced the management of systemic lupus erythematosus (SLE) . Beyond the initial Phase III randomised controlled trials (RCTs) that demonstrated efficacy for belimumab as an add-on to non-biological standard therapy (ST) along with a favourable safety profile, more than 50 post hoc analyses of RCT data have provided additional insights into its clinical utility. These analyses have shown uniformly that belimumab increases the likelihood of achieving meaningful reductions in disease activity, sustained low disease activity, and improved health-related quality of life (HRQoL) outcomes, with more pronounced benefits in serologically active SLE. Studies focusing on organ-specific manifestations revealed that belimumab confers benefits across multiple SLE facets, with prominent effects on musculoskeletal and mucocutaneous symptoms. Along the same lines, post hoc analyses of the BLISS-LN trial demonstrated benefit from belimumab regarding multiple renal outcomes, including reduced renal flare rates, improved glomerular filtration rate, and improved histological findings in repeat kidney biopsies. Long-term extension studies and real-world evidence confirm its durable efficacy and safety, with continued reductions in overall disease activity, glucocorticoid use, and healthcare resource utilisation over several years. By exploring different efficacy endpoints, person-centred outcomes, disease trajectories, and characteristics across organ manifestations, this body of postmarketing evidence has not only enhanced our understanding of belimumab use in SLE but also constitutes a comprehensive framework for future clinical trial design and development of novel therapeutic strategies. The present review summarises key findings of post hoc analyses of RCTs and observational studies of belimumab.  \nKeywords: systemic lupus erythematosus; belimumab; BLISS; post hoc analysis; outcome measures; belimumab; B cell therapies  \n1. Introduction  \nBelimumab is a monoclonal antibody that targets the B-lymphocyte stimulator (BLyS), a key factor in B cell survival and a contributor to the pathogenesis of systemic lupus erythematosus (SLE) [1] . It was first approved in 2011 for the treatment of moderately to highly active SLE based on the positive outcomes of two pivotal Phase III clinical trials: BLISS-52 [2] and BLISS-76 [3] . These studies demonstrated the efficacy and favourable safety of intravenous (i.v.) belimumab as an add-on therapy to non-biological standard therapy (ST) in patients with active, autoantibody-positive SLE. Following these initial trials,  \nthree additional studies (BLISS-NEA [4], EMBRACE [5], and BLISS-SC [6]) were conducted to further evaluate its effectiveness across more diverse patient populations and to assess the efficacy and convenience of the subcutaneous (s.c.) administration. Collectively, these trials enrolled over 3500 patients, making this clinica","cbCailppImAehD3v","https://ap.wps.com/l/cbCailppImAehD3v","pdf",395667,23,"English","# Abstract\n# Introduction\n# The Belimumab Trials\n## Table 1. Summary of belimumab trials","[{\"question\":\"What is belimumab and what mechanism does it target in SLE?\",\"answer\":\"Belimumab is a human monoclonal antibody that works against B-cell activating factor (BAFF). It targets pathways involving B-cell survival relevant to the pathogenesis of SLE.\"},{\"question\":\"What do post hoc analyses of belimumab RCT data show?\",\"answer\":\"Post hoc analyses indicate belimumab increases the likelihood of meaningful reductions in disease activity, sustained low disease activity, and improved health-related quality of life outcomes, with stronger effects in serologically active SLE.\"},{\"question\":\"What benefits are reported for renal outcomes in the BLISS-LN trial?\",\"answer\":\"The review reports benefits of belimumab across multiple renal outcomes, including reduced renal flare rates, improved glomerular filtration rate, and improved histological findings in repeat kidney biopsies.\"}]","Lessons Learnt from the Belimumab Trials in Systemic Lupus Erythematosus | PDF",1790764062,58]